Novartis delivered solid sales and profit growth in the first quarter of 2014

NovartisSubsequent to the quarter end, Novartis announced that it had reached definitive agreements with GlaxoSmithKline plc (GSK) and Eli Lilly and Company (Lilly) on a set of transactions. In an inter-conditional transaction with GSK: (1) Novartis agreed to acquire GSK oncology products and to become GSK's preferred commercialization partner for its oncology pipeline for a USD 14.5 billion payment and up to USD 1.5 billion contingent on a development milestone; (2) Novartis and GSK agreed to create a world-leading consumer healthcare business in a joint venture of which Novartis would own 36.5%; and (3) Novartis divested its Vaccines Division (excluding flu) to GSK for up to USD 7.1 billion plus royalties. The USD 7.1 billion consists of USD 5.25 billion upfront and up to USD 1.8 billion in milestones. In addition, Novartis agreed to divest its Animal Health Division to Lilly for approximately USD 5.4 billion.

These transactions are consistent with our strategy to lead through science-based innovation and would further accelerate our future growth. The acquisition of GSK oncology products would strengthen the Pharmaceuticals Division and Oncology business, leveraging its development and commercial capabilities. The creation of a world-leading consumer healthcare business with GSK would offer scale, complementary portfolios and complementary geographic footprint. The divestiture of Novartis Vaccines (excluding flu) to GSK would maximize the value of the Vaccines pipeline, including Bexsero, and create a global vaccines leader. The divestiture of the Animal Health Division to Lilly would recognize the full value of the business and an appropriate share of expected synergies, while creating a global animal health leader under Lilly's ownership.

These transactions would provide a strong financial proposition for Novartis. From year one after closing, we expect an improvement in growth rates of sales, core operating income and core operating income margin, with each component of the deals creating value.

All transactions are subject to closing conditions, including anti-trust approvals, and the GSK transaction is subject to approval by GSK shareholders. The transaction with Lilly is expected to close by the end of the first quarter of 2015 and the transaction with GSK is expected to close during the first half of 2015.

First quarter
Novartis completed the divestment of the blood transfusion diagnostics unit contained within its Vaccines and Diagnostics Division on January 9, 2014. The former Vaccines and Diagnostics unit is now called the Vaccines Division, effective from January 1, 2014. The pro forma data contained within this release excludes, from January 1, 2013, the results of the blood transfusion diagnostics unit from the 2013 Novartis Group and Vaccines and Diagnostics divisional data.[2] All comparisons to prior year for Group and Vaccines are versus pro forma.

Group net sales increased 1% (+3% cc) to USD 14.0 billion in the first quarter. Currency had a negative impact of 2 percentage points, mainly due to the weakened yen and weakening emerging market currencies against the US dollar, partly offset by a stronger euro. Growth products contributed USD 4.3 billion or 31% of Group net sales, up 17% (USD) over the prior-year quarter.

Group operating income increased 22% (+31% cc) to USD 3.5 billion, mainly due to a USD 0.9 billion exceptional gain from the divestment of the blood transfusion diagnostics unit to Grifols S.A. The negative currency impact of 9 percentage points was mainly due to the further strengthening of the Swiss franc and weakening of the yen and emerging market currencies in the first quarter. Operating income margin increased by 4.4 percentage points to 24.9% of net sales. The adjustments made to Group operating income to arrive at core operating income amounted to USD 0.2 billion (2013: USD 0.8 billion).

Core operating income was USD 3.7 billion (0%, +6% cc). Core operating income margin in constant currencies increased 0.9 percentage points due to improved core margins in Pharmaceuticals and lower corporate costs; currency had a negative impact of 1.1 percentage points, resulting in a net decline of 0.2 percentage points to 26.1% of net sales.

Group net income of USD 3.0 billion was up 24% in reported terms, and up 30% in constant currencies, largely due to higher operating income driven by the exceptional divestment gain and higher income from associated companies, offset by higher net financial expenses and higher income tax due to the exceptional divestment gain. EPS was up 25% (+30% cc) to USD 1.21 in line with net income.

Group core net income of USD 3.2 billion was stable in reported terms, but up 6% in constant currencies, from core operating income performance and higher income from associated companies, offset by higher net financial expenses. Core EPS increased 1% (+6% cc) to USD 1.31, in line with core net income.

Commenting on the results, Joseph Jimenez, CEO of Novartis, said: "Novartis delivered a solid quarter, with all divisions contributing to growth. We made progress in innovation, including EU and US approval of Xolair in chronic spontaneous urticaria and significant milestones for Bexsero. The transformational deals announced on Tuesday position the company for future success based on our sharpened focus, innovation power and financial strength."

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 135,000 full-time-equivalent associates and sell products in more than 150 countries around the world.

Most Popular Now

Chemists characterize the fatal fungus among us

Life-threatening fungal infections affect more than two million people worldwide. Effective antifungal medications are very limited. Until now, one of the major challenge...

FDA approves first cancer drug through new oncolog…

The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopa...

Discovery of kidney cancer driver could lead to ne…

University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic...

The immune system: T cells are built for speed

Without T cells, we could not survive. They are a key component of our immune system and have highly sensitive receptors on their surface that can detect pathogens. The e...

FDA approves first targeted treatment for patients…

The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (...

Women and older people under-represented in drug t…

Trying to determine how best to treat a patient, doctors often look to randomized clinical trials to guide their choice of what drug to prescribe. One of the most common ...

Novartis renews drug donation of Egaten® (triclabe…

Novartis reaffirms its commitment to the fight against liver fluke (fascioliasis), signing a renewed memorandum of understanding with the World Health Organization (WHO) ...

Pfizer initiates pivotal Phase 3 program for inves…

Pfizer Inc. (NYSE:PFE) and Spark Therapeutics (NASDAQ:ONCE) announced today that Pfizer initiated a Phase 3 open-label, multi-center, lead-in study (NCT03587116) to evalu...

Sanofi and REVOLUTION Medicines launch global part…

Sanofi and REVOLUTION Medicines, Inc. today announced an exclusive worldwide partnership to develop and commercialize targeted therapies, based on the biology of the cell...

Novartis marks a new era for migraine patients wit…

Novartis announced today that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days p...

FDA grants Breakthrough Therapy Designation for Ro…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq® (atezolizumab) i...

New findings suggest allergic responses may protec…

The components of the immune system that trigger allergic reactions may also help protect the skin against cancer, suggest new findings. The research, led by Imperial Col...